You Can Help
Contact
Forum
Shop
Search
Sign Up
Donate
You Can Help
What is ALS
Newly Diagnosed?
Treatments & ALS Drugs
Frequently Asked Questions
Glossary
ALS Research
Precision Medicine Program
Research News
Meet Our Scientists
Translational Research
Explore Our Lab
Publications
Help Fund Treatments
Donate
Start a Fundraiser
Events
ALS Awareness
Other Ways to Give
Corporate Opportunities
Shop
Resources
ALS Forum
ALS Clinical Trials
News
ALS Town Hall
Webinars
Podcasts
About Us
History
Team
Our Supporters
Schedule a Tour
Financials
Press Room
Contact Us
You Can Help
Contact
Forum
Shop
Search
Donate
Sign Up
Your support fuels our research to #EndALS!
Donate Now
ALS Clinical Trials
Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)
ALS Clinical Trials
Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)
Quick Info
Status
This study has been terminated
Phase
-
Trial Type
Expanded Access Protocol (EAP)
Treatment Type
Orally Disolving Tablet (Sublingual)
Randomization
Unknown
Enrollment
250
Start Date
Sponsor
Biohaven Pharmaceuticals, Inc.
Contact Information
1-888-315-5797 Ext 6
bhv0223.expandedaccess@earlyaccesscare.com
Locations
Anywhere in USA
Trial Goal
Tests to Expect
Open Label
Unknown
Update Notes
Recruitment status updated
7/29/2019
No significant updates.
7/9/2019
No significant updates
6/6/2018
Trial added
5/15/2018
Other Information
Purpose
This is an open label expanded access protocol for the treatment of up to approximately 250 adult patients with amyotrophic lateral sclerosis (ALS) who have difficulty swallowing oral riluzole tablets and may be able to derive benefit from treatment with an alternative oral formulation of riluzole.
Eligibility
Inclusion Criteria:
- Patients with diagnosed ALS of any type or duration - Current or previous treatment with oral riluzole tablets, or patients who have never taken riluzole oral tablets, or patients who have successfully completed a clinical trial with BHV-0223 and were not withdrawn prematurely due to adverse events - Swallowing difficulties, or patient or caregiver report choking one or more times per week, or investigator deems appropriate to treat with sublingual BHV-0223 because (s)he deems the patient cannot be satisfactorily treated with RilutekĀ® - Adequate hepatic function Exclusion Criteria:
- Patient with history of severe hypersensitivity reaction to riluzole oral tablets or BHV-0223 - Patient is known to have any other acute or chronic liver disease
Details
Riluzole is indicated in the U.S. for the treatment of patients with amyotrophic lateral sclerosis (ALS). The commercially available dosage form is a 50mg oral tablet. This expanded access protocol (EAP) is designed to provide access to a dissolving tablet formulation of riluzole designed for sublingual (SL) administration, in patients with ALS who, in the opinion and clinical judgement of the treating physician, would benefit from treatment with BHV-0223.
Collaborator(s)
Biohaven Pharmaceuticals, Inc.
Trial Protocol as Published on Clinicaltrials.gov
NCT03537807
(First Published: 5/9/2018)
What is ALS
ALS Research
Help Fund Treatments
Resources
About Us
Contact
Forum
Shop
Search
Donate
Sign Up
What is ALS
Overview
Newly Diagnosed?
Treatments & ALS Drugs
FAQS
Glossary
Contact
Forum
Shop
Search
Donate
Sign Up
ALS Research
Overview
Precision Medicine Program
Research News
Meet Our Scientists
Translational Research
Explore Our Lab
Publications
Contact
Forum
Shop
Search
Donate
Sign Up
Help Fund Treatments
Overview
Donate
Start a Fundraiser
Events
ALS Awareness
Other Ways To Give
Corporate Opportunities
Shop
Contact
Forum
Shop
Search
Donate
Sign Up
Resources
Overview
ALS Forum
ALS Clinical Trials
News
ALS Town Hall
Webinars
Podcasts
Contact
Forum
Shop
Search
Donate
Sign Up
About Us
Overview
History
Team
Our Supporters
Schedule a Tour
Financials
Press Room
Contact Us
Contact
Forum
Shop
Search
Donate
Sign Up
×
Want to Stay Up-to-Date?
Subscribe to our email list to get the latest updates on ALS research news, events, and clinical trials.
Subscribe